EXAGEN INC (XGN)

Company Profile

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 174 full-time employees. The company went IPO on 2019-09-19. The firm has developed and is commercializing a portfolio of testing products, under its AVISE brand. The company commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.

Company Info

EXAGEN INC

1261 Liberty Way

Vista CALIFORNIA 92081

P: 17605601501

CEO: Fortunato Ron Rocca

Employees: 177

Website: https://exagen.com/